131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases
Clinical trial NCT03275402 · TERMINATED
Trial details
- NCT number
- NCT03275402
- Sponsor
- Y-mAbs Therapeutics
- Status
- TERMINATED
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-11
- Primary completion
- 2023-06-02
- Enrollment
- 52
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.